XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.…
XORTX Completes Manufacturing of Clinical Drug Supply
XORTX Therapeutics (NASDAQ: XRTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.8390 USD on 20 November 2026, down 71.4% over 52 weeks. Its 52-week range is 0.8101 USD to 3.600 USD: the price is 76.7% below the high and 3.6% above the low.
Its market capitalisation is 1.88M USD.
XORTX Therapeutics reports return on equity of -127.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 318.85K USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health.